A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 in Patients With Advanced Solid Tumors With Homozygous MTAP Deletion

Trial ID: NCT05245500

Interventional - Phase 1 - Recruiting

This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.

Conditions

• Mesothelioma
• Non Small Cell Lung Cancer
• Malignant Peripheral Nerve Sheath Tumors
• Solid Tumor
• Pancreatic Adenocarcinoma
• Advanced Solid Tumor

Interventions

• MRTX1719

Eligibility

Inclusion criteria

• Histologically confirmed diagnosis of a solid tumor malignancy with homozygous deletion of the MTAP gene detected in tumor tissue.
• Unresectable or metastatic disease.
• Presence of a tumor lesion amenable to mandatory biopsy for pharmacodynamic evaluation at baseline and on-study unless Sponsor-confirmed as medically unsafe or infeasible.
• Age ≥ 18 years.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• Adequate organ function.

Exclusion criteria

• Prior treatment with a PRMT5 or MAT2A inhibitor therapy.
• Active brain metastases or carcinomatous meningitis.
• History of significant hemoptysis or hemorrhage within 4 weeks of the first dose of study treatment.
• Major surgery within 4 weeks of first dose of study treatment.
• History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions (eg, uncontrolled nausea, vomiting, malabsorption syndrome) likely to alter absorption of study treatment or result in inability to swallow oral medications.
• Cardiac abnormalities.
• Other protocol-defined Inclusion/Exclusion criteria apply.

Sponsor

Bristol-Myers Squibb

Source: ClinicalTrials.gov

Search more clinical trials on myTomorrows